CDC: Antibiotic Resistance Threats in the United States, 2019. (2019). Accessed.

De Rosa A, Mutters NT, Mastroianni CM, Kaiser SJ, Günther F. Distribution of carbapenem resistance mechanisms in clinical isolates of XDR Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2019;38(8):1547–52. https://doi.org/10.1007/s10096-019-03585-0.

Article  CAS  PubMed  Google Scholar 

Raible KM, Sen B, Law N, Bias TE, Emery CL, Ehrlich GD, et al. Molecular characterization of β-lactamase genes in clinical isolates of carbapenem-resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob. 2017;16(1):75. https://doi.org/10.1186/s12941-017-0248-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396–401. https://doi.org/10.1128/aac.01405-16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother. 2016;60(7):4384–6. https://doi.org/10.1128/aac.03098-15.

Article  PubMed  PubMed Central  Google Scholar 

Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato J, Hisakawa S, et al. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018;155:847–68. https://doi.org/10.1016/j.ejmech.2018.06.014.

Article  CAS  PubMed  Google Scholar 

Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clinical Infectious Diseases. 2019;69(Supplement_7):S538-S43. doi: https://doi.org/10.1093/cid/ciz826.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017;61(9):e00093-e117. https://doi.org/10.1128/AAC.00093-17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62(2):e01968-e2017. https://doi.org/10.1128/AAC.01968-17.

Article  PubMed  PubMed Central  Google Scholar 

Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016;71(3):670–7. https://doi.org/10.1093/jac/dkv402.

Article  CAS  PubMed  Google Scholar 

CLSI. Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI guideline M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.

Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 2018;62(1):e01454-e1517. https://doi.org/10.1128/AAC.01454-17.

Article  PubMed  Google Scholar 

Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N. In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant gram-negative bacteria. antimicrobial agents and chemotherapy. 2020;64(12):e01582–20. doi: https://doi.org/10.1128/AAC.01582-20.

Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019. Antimicrob Agents Chemother. 2022;66(2):e0199021. doi: https://doi.org/10.1128/aac.01990-21.

Poirel L, Sadek M, Nordmann P. Contribution of PER-type and NDM-Type β-lactamases to cefiderocol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2021;65(10):e0087721. doi: https://doi.org/10.1128/aac.00877-21.

Malik S, Kaminski M, Landman D, Quale J. Cefiderocol resistance in Acinetobacter baumannii: roles of β-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrob Agents Chemother. 2020;64(11). https://doi.org/10.1128/aac.01221-20.

• Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect Dis. 2021;21(5):597–8. https://doi.org/10.1016/s1473-3099(21)00194-8.) Surveillance study of carbapenem-resistant pathogens. Similar to other studies, resistance to cefiderocol was low, however population analysis profiling indicated higher rates of heteroresistance to cefiderocol, especially in Acinetobacter isolates (59%).

Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):e02163-e2217. https://doi.org/10.1128/AAC.02163-17.

Article  PubMed  PubMed Central  Google Scholar 

Miyazaki S, Katsube T, Shen H, Tomek C, Narukawa Y. Metabolism, excretion, and pharmacokinetics of [14C]-cefiderocol (S-649266), a siderophore cephalosporin, in healthy subjects following intravenous administration. J Clin Pharmacol. 2019;59(7):958–67. https://doi.org/10.1002/jcph.1386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol. 2017;57(5):584–91. https://doi.org/10.1002/jcph.841.

Article  CAS  PubMed  Google Scholar 

Katsube T, Saisho Y, Shimada J, Furuie H. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother. 2019;74(7):1971–4. https://doi.org/10.1093/jac/dkz123.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takemura M, Kanazawa S, Kohira N, Aoe Y, Morimoto A, Horiuchi K, et al. 1106. Evaluation of penetration of cefiderocol into cerebrospinal fluid using a rat meningitis model. Open Forum Infectious Diseases. 2021;8(Supplement_1):S645-S. doi: https://doi.org/10.1093/ofid/ofab466.1300.

Katsube T, Wajima T, Ishibashi T, Ferreira JCA, Echols R. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2017;61(1):e01381-e1416. https://doi.org/10.1128/AAC.01381-16.

Article  CAS  PubMed  Google Scholar 

Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019;63(9). https://doi.org/10.1128/aac.02031-18.

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319-28. https://doi.org/10.1016/S473-3099(18)30554-1. Epub 2018 Oct 25.

Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–25. https://doi.org/10.1016/s1473-3099(20)30731-3.

Article  CAS  PubMed  Google Scholar 

• Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226-40. https://doi.org/10.1016/s1473-3099(20)30796-9. Randomized, open-label, controlled trial designed to study the use of cefiderocol for infections caused by carbapenem-resistant Gram-negative pathogens.

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169-e83. https://doi.org/10.1093/cid/ciaa1478.

• Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022:e0214221. https://doi.org/10.1128/aac.02142-21. Retrospective, observational study examining cefiderocol- and colistin-based regimens for the treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Cefiderocol was more commonly utilized as part of a combination regimen than in randomized trials.

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab1013.

Article  PubMed  PubMed Central  Google Scholar 

Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72(11):2021–4. https://doi.org/10.1093/cid/ciaa1410.

Article  CAS  PubMed  Google Scholar 

Fratoni AJ, Kuti JL, Nicolau DP. Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2021;58(3):106395. https://doi.org/10.1016/j.ijantimicag.2021.106395.

Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, et al. Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2020;64(9):e00559-e620. https://doi.org/10.1128/AAC.00559-20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bleibtreu A, Dortet L, Bonnin RA, Wyplosz B, Sacleux S-C, Mihaila L, et al. Susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study. Microorganisms. 2021;9(2):282. https://doi.org/10.3390/microorganisms9020282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdul-Mutakabbir JC, Nguyen L, Maassen PT, Stamper KC, Kebriaei R, Kaye KS, et al. In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2021;65(9):e0264620. https://doi.org/10.1128/aac.02646-20.

Stevens RW, Clancy M. Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug-resistant Pseudomonas aeruginosa: a case report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019;39(11):1113–8. https://doi.org/10.1002/phar.2334.

Kufel WD, Steele JM, Riddell SW, Jones Z, Shakeraneh P, Endy TP. Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: clinical observations and susceptibility testing considerations. IDCases. 2020;21:e00863. https://doi.org/10.1016/j.idcr.2020.e00863.

Edgeworth JD, Merante D, Patel S, Young C, Jones P, Vithlani S, et al. Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2018;68(11):1932–4. https://doi.org/10.1093/cid/ciy963.

Article  CAS  PubMed Central  Google Scholar 

Zingg S, Nicoletti GJ, Kuster S, Junker M, Widmer A, Egli A, et al. Cefiderocol for extensively drug-resistant Gram-negative bacterial infections: real-world experience from a case series and review of the literature. Open Forum Infect Dis. 2020;7(6):ofaa185. https://doi.org/10.1093/ofid/ofaa185.

Bodro M, Hernández-Meneses M, Ambrosioni J, Linares L, Moreno A, Sandoval E, et al. Salvage treatment with cefiderocol regimens in two intravascular foreign body infections by MDR Gram-negative pathogens, involving non-removable devices. Infectious Diseases and Therapy. 2021;10(1):575–81. https://doi.org/10.1007/s40121-020-00385-4.

Article  PubMed  PubMed Central  Google Scholar 

Grande Perez C, Maillart E, Miendje Deyi VY, Huang TD, Kamgang P, Dernier Y, et al. Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance. Infect Dis Now. 2021;51(4):399–401. https://doi.org/10.1016/j.medmal.2020.10.022.

Article  CAS  PubMed  Google Scholar 

Cipko K, Kizny Gordon A, Adhikari S, Konecny P. Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis. Int J Infect Dis. 2021;109:108–11. https://doi.org/10.1016/j.ijid.2021.06.035.

Article  CAS  PubMed  Google Scholar 

König C, Both A, Rohde H, Kluge S, Frey OR, Röhr AC, et al. Cefiderocol in critically ill patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance. Antibiotics (Basel). 2021;10(6). https://doi.org/10.3390/antibiotics10060649.

Bavaro DF, Belati A, Diella L, Stufano M, Romanelli F, Scalone L, et al. Cefiderocol-based combination therapy for "difficult-to-treat" Gram-negative severe infections: real-life case series and future perspectives. Antibiotics (Basel). 2021;10(6). https://doi.org/10.3390/antibiotics10060652.

Trecarichi EM, Quirino A, Scaglione V, Longhini F, Garofalo E, Bruni A, et al. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. J Antimicrob Chemother. 2019;74(11):3399–401. https://doi.org/10.1093/jac/dkz318.

Article  CAS  PubMed  Google Scholar 

Alamarat ZI, Babic J, Tran TT, Wootton SH, Dinh AQ, Miller WR, et al. Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-b-lactamase-Producing Klebsiella pneumoniae in a pediatric patient. Antimicrob Agents Chemother. 2020;64(4):e01872-e1919. https://doi.org/10.1128/AAC.01872-19.

Article  PubMed  PubMed Central